Aurobindo Pharma Ltd.
Snapshot View

403.90 -6.00 ▼-1.5%

03 February 2023, 04:01:00 PM
Volume: 38,257

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.aurobindo.com
Market Cap 23,666.06 Cr.
Enterprise Value(EV) 22,282.31 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) 36.03 Trailing Twelve Months Ending 2022-09
Price-Earning Ratio (PE) 11.21 Trailing Twelve Months Ending 2022-09
Industry PE 32.22 Trailing Twelve Months Ending 2022-09
Book Value / Share 435.68 Trailing Twelve Months Ending 2022-09
Price to Book Value 0.93 Calculated using Price: 403.90
Dividend Yield 2.23 Period Ending 2022-03
No. of Shares Subscribed 58.59 Cr. 585,938,609 Shares
FaceValue 1
Company Profile
Aurobindo Pharma continues to be one of the world's fastest growing Active Pharmaceutical Ingredients (API) manufacturing companies, driven by cost leadership, flexibility to produce multiple products in the same manufacturing facilities and capabilities in various therapeutic domains. Its API business has ensured the profitability and growth of its formulations business through seamless vertical integration. Its API business is supported by technologically advanced research and development infrastructure, which develops new products and plays a role in the delivery of products to the market. It has built a strong presence in key therapeutic segments such as Central nervous system (CNS), cardiovascular (CVS), anti-retroviral (ARV), anti-diabetics, gastroenterology and antibiotics. Also, it is building a diversified pipeline in high-margin specialty generic formulations segment.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
-1.46%
1 Week
-2.97%
1 Month
-8.45%
3 Month
-27.62%
6 Month
-27.46%
1 Year
-39.76%
2 Year
-56.10%
5 Year
-33.25%
10 Year
+320.82%
9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 36.79 35.29 32.51 27.57 22.99 18.47 18.62 27.81 11.52
Return on Capital Employed (%) 27.18 27.18 27.35 24.92 22.72 17.97 18.79 30.33 12.82
Return on Assets (%) 13.95 14.03 14.13 14.44 13.07 10.00 10.39 17.34 7.99

Balance Sheet View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds 3,750 5,156 7,287 9,372 11,680 13,891 16,825 21,930 24,576 25,528
Non Curr. Liab. 1,494 1,592 584 102 594 358 555 807 903 809
Curr. Liab. 4,220 6,136 7,840 6,606 8,666 12,021 11,385 10,665 8,156 10,450
Minority Int. 26 26 3 2 2 2 0 -1 -2 13
Equity & Liab. 9,490 12,910 15,714 16,082 20,942 26,271 28,765 33,401 33,633 36,799
Non Curr. Assets 3,859 4,611 5,420 6,875 8,764 10,939 12,352 13,578 15,510 16,571
Curr. Assets 5,631 8,299 10,294 9,206 12,178 15,332 16,413 19,824 18,123 20,228
Misc. Exp. not W/O
Total Assets 9,490 12,910 15,714 16,082 20,942 26,271 28,765 33,401 33,633 36,799

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09 Rs. Cr. TTM
Net Sales 8,100 12,121 13,795 14,910 16,463 19,564 23,099 24,775 23,455 23,787
Other Income 22 97 204 116 102 155 192 381 323 212
Total Income 8,121 12,217 13,998 15,025 16,565 19,719 23,290 25,155 23,778 23,999
Total Expenditure -5,966 -9,557 -10,607 -11,475 -12,691 -15,612 -18,234 -19,441 -19,071 -20,069
PBIDT 2,155 2,660 3,392 3,550 3,874 4,107 5,056 5,714 4,707 3,930
Interest -310 -160 -257 -67 -78 -263 -305 -74 -49 -65
Depreciation -313 -333 -392 -428 -558 -668 -967 -1,055 -1,127 -1,130
Taxation -363 -597 -721 -760 -818 -727 -899 -2,010 -726 -479
Exceptional Items -88 -26 2,815 -128 -128
PAT 1,169 1,571 2,022 2,296 2,420 2,362 2,859 5,389 2,678 2,128
Minority Interest 4 5 2 0 0 0 1 1 1
Share Associate 1 5 3 3 -15 -55 -31 -16
Other Related Items
Consolidated Net Profit 1,173 1,576 2,025 2,302 2,423 2,365 2,845 5,335 2,648 2,111
Adjusted EPS 20 27 35 39 41 40 49 91 45 36

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 275 646 1,237 1,420 3,279 1,955 1,651 4,381 3,329 5,016
Cash Fr. Inv. -246 -819 -1,398 -1,445 -1,787 -1,927 -2,903 -1,568 599 -3,212
Cash Fr. Finan. 108 118 93 365 -1,915 864 1,919 -1,947 -1,365 -2,969
Net Change 137 -55 -68 340 -424 892 667 866 2,563 -1,164
Cash & Cash Eqvt 203 148 461 744 320 1,210 1,876 2,747 5,330 4,163

Shareholding Pattern View Details >>

9 Qtrs 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%)
Promoter 51.94 51.94 51.83 51.83 51.83 51.83 51.83 51.83 51.83
Public 48.06 48.06 48.17 48.17 48.17 48.17 48.17 48.17 48.17
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 9.27 22.81 20.66 22.98 22.97 14.05 14.97 14.92 16.15

Announcements View Details >>

Fri, 03 Feb 2023
Intimation Of Record Date Pursuant To Regulation 42 Of The Securities & Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015.
Further to our letter dated January 31 2023 intimating the date of Board Meeting to be held on February 9 2023 inter alia to consider unaudited financial results for the quarter and nine months period ended December 31 2022 and interim dividend for the FY 2022-23 and pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 we hereby inform that the interim dividend if declared shall be paid to the equity shareholders of the Company whose names appear on the Register of Members as on February 17 2023 which is the Record Date fixed for this purpose.
Fri, 03 Feb 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we are enclosing herewith the schedule of Earnings Call to be held on February 10 2023 at 8:30 AM (IST) on Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31 2022.
Tue, 31 Jan 2023
Board Meeting Intimation for Intimation Of Board Meeting
AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2023 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform that a Meeting of the Board of Directors of the Company will be held on Thursday February 9 2023 to consider and approve inter alia the following:1. Standalone & Consolidated Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31 2022 and2. Payment of Interim Dividend if any for the financial year 2022-23.Further to our letter dated December 29 2022 informing about the closure of Trading Window of the Company from January 1 2023 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31 2022 we inform you that the Trading Window will remain closed up to February 11 2023 and shall be re-opened on February 12 2023.

Technical Scans View Details >>

Fri, 03 Feb 2023
Close Crossing Last Week Low Close Crossing Last Week Low
Close Crossing Last Month Low Close Crossing Last Month Low
Close Crossing Last Month Close from Above Close Crossing Last Month Close from Above
Close Crossing 52 Week Low Close Crossing 52 Week Low
Closing Below Previous Low Closing Below Previous Low

Related Stocks View Details >>

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 246,567.66 1,027.65 +2.0%
Cipla Ltd. 82,812.97 1,026.00 +0.1%
Divi's Laboratories Ltd. 76,573.08 2,884.45 -11.7%
Dr. Reddy's Laboratories Ltd. 72,577.66 4,358.40 -0.3%
Apollo Hospitals Enterprise Ltd. 61,039.46 4,245.20 +0.3%
Torrent Pharmaceuticals Ltd. 52,289.82 1,545.00 +0.3%
Abbott India Ltd. 44,198.55 20,800.00 +1.5%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 58.54 1,027.65 +2.0%
Cipla Ltd. Consolidated 2022-12 31.39 1,026.00 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-09 25.59 2,884.45 -11.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 19.92 4,358.40 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 72.70 4,245.20 +0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 62.92 1,545.00 +0.3%
Abbott India Ltd. Standalone 2022-09 50.12 20,800.00 +1.5%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 4.46 1,027.65 +2.0%
Cipla Ltd. Consolidated 2022-12 3.65 1,026.00 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-09 6.31 2,884.45 -11.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.30 4,358.40 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 10.20 4,245.20 +0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 8.20 1,545.00 +0.3%
Abbott India Ltd. Standalone 2022-09 16.28 20,800.00 +1.5%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 1,027.65 +2.0%
Cipla Ltd. Consolidated 2022-03 0.04 1,026.00 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 2,884.45 -11.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,358.40 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,245.20 +0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,545.00 +0.3%
Abbott India Ltd. Standalone 2022-03 0.00 20,800.00 +1.5%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,027.65 +2.0%
Cipla Ltd. Consolidated 2022-03 13.10 1,026.00 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,884.45 -11.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,358.40 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,245.20 +0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,545.00 +0.3%
Abbott India Ltd. Standalone 2022-03 29.95 20,800.00 +1.5%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,027.65 +2.0%
Cipla Ltd. Consolidated 2022-03 13.10 1,026.00 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,884.45 -11.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,358.40 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,245.20 +0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,545.00 +0.3%
Abbott India Ltd. Standalone 2022-03 29.95 20,800.00 +1.5%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,027.65 +2.0%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,026.00 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 2,884.45 -11.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,358.40 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,245.20 +0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,545.00 +0.3%
Abbott India Ltd. Standalone 2022-03 4,919.27 20,800.00 +1.5%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,027.65 +2.0%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,026.00 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 2,884.45 -11.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,358.40 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,245.20 +0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,545.00 +0.3%
Abbott India Ltd. Standalone 2022-03 798.70 20,800.00 +1.5%

FAQ's On Aurobindo Pharma Ltd.

What is Aurobindo Pharma share price?

Can I buy Aurobindo Pharma shares now?

What is the Dividend Yield of Aurobindo Pharma?

What is the Market Cap of Aurobindo Pharma?

What are the key metrics to analyse Aurobindo Pharma?

What is the 52 Week High and Low of Aurobindo Pharma?

What is the trend of Aurobindo Pharma share price?